Literature DB >> 8772714

T-cell responses to autoantigens in IDDM. The search for the Holy Grail.

B O Roep1.   

Abstract

IDDM (type I diabetes) is generally believed to result from T-cell-mediated autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans. In the last few years, considerable progress has been made with regard to the identification and characterization of candidate autoantigens recognized by autoantibodies; several of these candidate autoantigens are recognized by T-cells, including insulin, GAD65 and GAD67, heat-shock protein 65 (hsp65), and islet-cell antigen 69 (ICA69). In addition to these, a number of unidentified beta-cell antigens, including insulin-secretory granule membrane proteins and a 38-kDa protein, have been shown to stimulate T-cells of IDDM patients. However, T-cell autoreactivity to islet antigens is not specific for IDDM, and the T-cell target antigens are not specific for beta-cells. Moreover, the autoantigens involved in the initiation of the insulitis must be defined, and the mechanism of the T-cell-dependent beta-cell destruction remains to be unraveled. This review focuses on T-cell autoreactivity in IDDM in humans and the implications of the present knowledge for immunointervention and monitoring of immunotherapeutic trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772714     DOI: 10.2337/diab.45.9.1147

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  36 in total

Review 1.  T-cell reactivity to beta-cell antigens in human insulin-dependent (type 1) diabetes mellitus. Implications for diagnosis and therapy.

Authors:  B O Roep
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  Controversial topics series: milk proteins and diabetes.

Authors:  J M Norris; M Pietropaolo
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

4.  Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase.

Authors:  H S Hiemstra; N C Schloot; P A van Veelen; S J Willemen; K L Franken; J J van Rood; R R de Vries; A Chaudhuri; P O Behan; J W Drijfhout; B O Roep
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

5.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.

Authors:  Sefina Arif; Timothy I Tree; Thomas P Astill; Jennifer M Tremble; Amanda J Bishop; Colin M Dayan; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 6.  The case for an autoimmune aetiology of type 1 diabetes.

Authors:  S I Mannering; V Pathiraja; T W H Kay
Journal:  Clin Exp Immunol       Date:  2015-10-21       Impact factor: 4.330

7.  Genes mediating environment interactions in type 1 diabetes.

Authors:  Erik Biros; Margaret A Jordan; Alan G Baxter
Journal:  Rev Diabet Stud       Date:  2006-02-10

8.  The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries.

Authors:  H S Hiemstra; G Duinkerken; W E Benckhuijsen; R Amons; R R de Vries; B O Roep; J W Drijfhout
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

Review 9.  Deciphering the Pathogenesis of Human Type 1 Diabetes (T1D) by Interrogating T Cells from the "Scene of the Crime".

Authors:  Sally C Kent; Stuart I Mannering; Aaron W Michels; Jenny Aurielle B Babon
Journal:  Curr Diab Rep       Date:  2017-09-02       Impact factor: 4.810

10.  Islet inflammation and CXCL10 in recent-onset type 1 diabetes.

Authors:  B O Roep; F S Kleijwegt; A G S van Halteren; V Bonato; U Boggi; F Vendrame; P Marchetti; F Dotta
Journal:  Clin Exp Immunol       Date:  2010-01-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.